Sei Investments Co. Increases Stock Position in LivaNova PLC (NASDAQ:LIVN)

Sei Investments Co. increased its position in LivaNova PLC (NASDAQ:LIVN) by 5.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 107,768 shares of the company’s stock after acquiring an additional 5,468 shares during the period. Sei Investments Co. owned about 0.20% of LivaNova worth $5,908,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board purchased a new position in LivaNova in the 2nd quarter worth approximately $88,000. Intech Investment Management LLC purchased a new position in LivaNova in the 2nd quarter worth approximately $481,000. Primecap Management Co. CA raised its holdings in LivaNova by 0.7% in the 2nd quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock worth $327,889,000 after acquiring an additional 44,049 shares during the last quarter. WINTON GROUP Ltd raised its holdings in LivaNova by 137.0% in the 2nd quarter. WINTON GROUP Ltd now owns 17,067 shares of the company’s stock worth $936,000 after acquiring an additional 9,865 shares during the last quarter. Finally, TradeLink Capital LLC purchased a new position in LivaNova in the 2nd quarter worth approximately $208,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Trading Up 0.0 %

Shares of LIVN stock opened at $52.54 on Tuesday. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47. The firm has a fifty day moving average price of $48.67 and a 200-day moving average price of $53.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.45 and a quick ratio of 2.94. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -87.57 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The firm had revenue of $318.60 million during the quarter, compared to the consensus estimate of $305.05 million. As a group, equities analysts predict that LivaNova PLC will post 2.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on LIVN shares. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Robert W. Baird raised shares of LivaNova from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $55.00 to $66.00 in a research report on Tuesday, September 17th. Needham & Company LLC lifted their target price on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, Stifel Nicolaus lifted their target price on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Buy” and a consensus target price of $70.80.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.